Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Von der Leyen faces scrutiny over shaky EU vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Faces grilling at four EU lawmaker group meetings

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Adds EU lawmaker meetings, and comments by MEP, senior
diplomat)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU chief executive Ursula von
der Leyen on Tuesday faced hours of questioning by lawmakers
over the European Commission's vaccine strategy, focusing on a
slow roll-out and an export control plan that dismayed Britain
and Ireland.

Questions still surround the Commission's decision - swiftly
reversed - to invoke Article 16 of the Brexit agreement's
Northern Ireland protocol, a move that would have set up border
checks on the island of Ireland.

Von der Leyen, who has tweeted and appeared only on German
television since the bloc mandated authorisation for vaccine
exports, will be quizzed in meetings of three European
Parliament groupings on Tuesday evening and another on Wednesday
morning.

Sophie in 't Veld, a Dutch liberal lawmaker, said before her
group met that von der Leyen was relying on too narrow a circle
of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

A senior EU diplomat said von der Leyen's position was
probably safe with a closing of ranks around the Commission, but
there would be "some unpleasantness in coming days".

Senior British minister Michael Gove, who is to meet his
Commission counterpart on Wednesday, said London's trust in
Brussels had been eroded and that the two must resolve serious
problems over post-Brexit trade arrangements for Northern
Ireland.

REGRET OVER 'PROVISIONAL' DECISION

In interviews with newspapers outside Germany, the European
Commission president sought to defuse criticism over the EU's
slow start to COVID-19 vaccinations and outrage over the border
checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

In similar comments to France's Le Monde she said: "When you
take urgent decisions - in this year of crisis, the Commission
has taken almost 900 - there is always a risk of missing
something."

The vaccine crisis, which came to a head with EU export
controls announced on Friday, followed news that AstraZeneca
would cut its supply of vaccines to the bloc until March
by 60% due to production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the supply problems should ease in the
second quarter of 2021, with more production capacity for
BioNTech/Pfizer and other potential approvals
of vaccines, including from Johnson & Johnson.

The Commission has ordered 2.3 billion doses from six
producers, far more than the bloc requires. Production, though,
was an enormous challenge, with clear teething problems.

"I see it as a marathon in which we have only covered the
first kilometres," she told Dutch newspaper De Volkskrant.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones and Angus MacSwan)

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.